<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250722066594N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-20</date_registration>
      <primary_sponsor>Khoram-Abad University of Medical Sciences</primary_sponsor>
      <public_title>The effect of salbutamol nebulizer on respiratory distress in term infants with transient neonatal tachypnea admitted to the NICU</public_title>
      <acronym>TTN</acronym>
      <scientific_title>The effect of salbutamol nebulized on respiratory distress in term infants with transient neonatal tachypnea admitted to the NICU</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>116</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/85132</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: A triple-blind, randomized clinical trial will be conducted on newborns. In the first stage, participants will be selected via purposive sampling from among those who meet the study's inclusion criteria and for whom parents have provided written informed consent. Participants will then be randomly assigned to either an intervention group or a control group using a balanced block randomization method (with a block size of four). Randomization will be performed prior to the commencement of participant recruitment; codes—designated as 'A' (intervention group) and 'B' (control group)—will be established, and their sequence determined. Specifically, the following four-item combinations will be generated: AABB, ABAB, ABBA, BABA, BBAA, and BAAB. A six-sided die (numbered 1 through 6) will then be used to randomly select these combinations, thereby establishing the allocation sequence (the allocation list) for assigning individuals to the intervention and control groups. The allocation list will be kept confidential by the physician (principal investigator). It should be noted that randomization will be performed separately for each hospital (Shahid Rahimi and Shahid Madani).
Once an individual is determined by the physician (principal investigator) to be eligible for the study, they will be assigned to the appropriate group based on the allocation list. To ensure that neither the parents nor the assessor are aware of the group assignment, each study participant will be assigned a random, non-sequential four-digit number, which will be recorded in the allocation list. The physician will document this four-digit number in the participant's medical record. The team’s statistician, who is responsible for data analysis, will have no direct contact with the participants and will not be involved in data collection, Blinding description: In this study, a triple-blind design is employed (involving parents/participants, the outcome assessor, and the statistical analyst). Regarding the implementation procedure: the randomization sequence (allocation list) is generated prior to the start of the study, separately for each of the two hospitals (Shahid Rahimi and Shahid Madani). This list is kept confidential by a department supervisor—who has no involvement in recruitment, intervention, assessment, or analysis—and remains inaccessible to the recruiting physician and the assessor. Once an infant is deemed eligible by the physician (supervising faculty member) and parental consent is obtained, the infant is assigned to a group based on the next entry in the allocation list. Consequently, the physician remains unaware of the upcoming group assignment prior to determining eligibility, thereby preventing selective enrollment (allocation concealment). To ensure parental blinding, parents are not informed of their infant’s group assignment. To blind the outcome assessor, each participant is assigned a random, non-sequential four-digit code, which is recorded in the allocation list; the physician enters only this code into the patient’s medical record. Thus, when evaluating outcomes, the assessor encounters only the code, from which the intervention or control group cannot be identified. Both the intervention (inhaled salbutamol) and the control (distilled water) are prepared in identical, unlabeled vials—appearing as clear, colorless solutions—and the method of administration (nebulizer), the device used, and the duration and conditions of the procedure are identical for both groups. The preparation and delivery of the solution, based on the allocation list, are carried out by an independent nurse who is not involved in the assessment of outcomes. The outcome assessor is not present at the bedside during the intervention; instead, they assess the outcomes only after the intervention is complete, using the participant’s four-digit code. Consequently, the assessor cannot determine the participant's assigned group based on the appearance or odor of the medication, nor through the method of administration.
Similarly, the statistician responsible for data analysis has no direct contact with the participants and is not involved in data collection. The analysis is performed using the four-digit codes, and the allocation list is not made available to the statistician until the final analysis is complete. In the event of a serious adverse event that necessitates knowledge of the participant's group assignment, the blinding is broken only for that specific individual, subject to approval by the department head.

بهینه‌سازی با ChatGPT.</study_design>
      <phase>2-3</phase>
      <hc_freetext>transient neonatal tachypnea admitted.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group A receives inhaled salbutamol (Ventolin) at a dosage of 0.1 mg/kg. The salbutamol is manufactured by Shahid Ghazi Pharmaceutical Company, with each 2.5 ml ampoule containing 2.5 mg of salbutamol. Intervention 2: Control group B receives a placebo consisting of 0.1 mg/kg of distilled water; 5 mL vials of distilled water produced by Shahid Ghazi Pharmaceutical Company were used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is At the decision-making stage</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zeynab PirdadehKHani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Enghelab</address>
        <city>KHorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1111111111</zip>
        <telephone>+98 66 0000 0000</telephone>
        <email>zpirdadeh@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zeynab PirdadehKHani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Enghelab</address>
        <city>KHorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1111111111</zip>
        <telephone>+98 66 0000 0000</telephone>
        <email>zpirdadeh@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Gestational age is greater than 37 weeks.
Tachypnea with more than 60 breaths per minute in the first 6 hours
Lung radiography findings include: congestion and prominence of the navel of the lungs, flattening of the diaphragm, airiness of the lungs, pleural effusion, filling of the horizontal and oblique fissures between the lung lobes.</inclusion_criteria>
      <agemin>1 day</agemin>
      <agemax>1 day</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Congenital abnormalities
Birth Asphyxia
Meconium Aspiration Syndrome
Congenital Heart Diseases Based on Echocardiography
Respiratory Distress Syndrome (RDS)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P28.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Respiratory failure of newborn</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group A receives inhaled salbutamol (Ventolin) at a dosage of 0.1 mg/kg. The salbutamol is manufactured by Shahid Ghazi Pharmaceutical Company, with each 2.5 ml ampoule containing 2.5 mg of salbutamol.</i_keyword>
      <i_keyword>Control group B receives a placebo consisting of 0.1 mg/kg of distilled water; 5 mL vials of distilled water produced by Shahid Ghazi Pharmaceutical Company were used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Infant respiratory distress score. Timepoint: 0-24. Method of measurement: Information collection form.</prim_outcome>
      <prim_outcome>Duration of infant hospitalization. Timepoint: 0-24. Method of measurement: Information collection form.</prim_outcome>
      <prim_outcome>Duration of oxygen therapy. Timepoint: 0-24. Method of measurement: Information collection form.</prim_outcome>
      <prim_outcome>Time of initiation of enteral feeding. Timepoint: 0-24. Method of measurement: Information collection form.</prim_outcome>
      <prim_outcome>Infant oxygen saturation percentage. Timepoint: 0-24. Method of measurement: Information collection form.</prim_outcome>
      <prim_outcome>Duration of tachypnea. Timepoint: 0-24. Method of measurement: Information collection form.</prim_outcome>
      <prim_outcome>Duration of oxygen therapy for infants. Timepoint: 0-24. Method of measurement: Information collection form.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Personal</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-04-28</approval_date>
        <contact_name>Ethics committee of Lorestan University of Medical Sciences</contact_name>
        <contact_address>No. 137, Araste 5, Enghelab ., Khorramabad city KHorramabad Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
